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://dSummary
This study is based on the Swiss Canine Cancer Registry, comprising 121,963 diagnostic records of dogs
compiled between 1955 and 2008, in which 63,214 (51.83%) animals were diagnosed with tumour lesions
through microscopical investigation. Adenoma/adenocarcinoma (n ¼ 12,293, 18.09%) was the most frequent
tumour diagnosis. Other common tumour diagnoses were: mast cell tumour (n ¼ 4,415, 6.50%), lymphoma
(n¼ 2,955, 4.35%), melanocytic tumours (n¼ 2,466, 3.63%), fibroma/fibrosarcoma (n¼ 2,309, 3.40%), hae-
mangioma/haemangiosarcoma (n¼ 1,904, 2.80%), squamous cell carcinoma (n¼ 1,324, 1.95%) and osteoma/
osteosarcoma (n ¼ 842, 1.24%). The relative occurrence over time and the most common body locations of
those tumour diagnoses are presented.
Analyses of the influence of age, breed, body size, sex and neutering status on tumour development were car-
ried out using multiple logistic regression. In certain breeds/breed categories the odds ratios (ORs) for partic-
ular tumours were outstandingly high: the boxer had higher ORs for mast cell tumour and haemangioma/
haemangiosarcoma, as did the shepherd group for haemangioma/haemangiosarcoma, the schnauzer for squa-
mous cell carcinoma and the rottweiler for osteoma/osteosarcoma. In small dogs, the risk of developing mam-
mary tumours was three times higher than in large dogs. However, small dogs were less likely to be affected by
many other tumour types (e.g. tumours of the skeletal system).
Examination of the influence of sex and neutering status on tumour prevalence showed that the results
depend on the examination method. In all sampling groups the risk for female dogs of developing adenoma/
adenocarcinoma was higher than for male dogs. Females had a lower risk of developing haemangioma/hae-
mangiosarcoma and squamous cell carcinoma than males. Neutered animals were at higher risk of developing
specific tumours outside the genital organs than intact animals.ondence to: A. Pospischil. (e-mail: apos@vetpath.uzh.ch).
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Analysis of the Swiss Canine Cancer Registry 157The sample size allows detailed insight into the influences of age, breed, body size, sex and neutering status on
canine tumour development. In many cases, the analysis confirms the findings of other authors. In some cases,
the results are unique or contradict other studies, implying that further investigations are necessary.
 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: cancer registry; dog; statistical analyses; tumourIntroduction
To meet the challenge posed by the combination of
potential aetiological factors in cancer, patient data
and diagnoses need to be explored systematically
(MacVean et al., 1978; Brønden et al., 2007, 2010;
Vascellari et al., 2009; Dobson, 2013; Waters et al.,
2014). This is the cornerstone of any
epidemiological study of cancer that aims to
investigate cancer development patterns in defined
populations over time and space. The
epidemiological study of cancer is therefore
dependent on the availability of patient data, which
are usually stored in cancer registries.
In this context, the study of companion animal can-
cer registries is especially valuable. Firstly, compan-
ion animals and their owners share the same
environment and are therefore mostly exposed to
the same environmental cancer risk factors
(Bukowski and Wartenberg, 1997; Backer et al.,
2001; Gamlem et al., 2008; Marconato et al., 2009;
Bettini et al., 2010). Secondly, similar genetic
predisposing factors for cancer development have
been found for man and animals (Jonasdottir et al.,
2000; Patterson, 2000; Lingaas et al., 2003; Breen,
2009; Pastor et al., 2009; Phillips et al., 2010; Ke
et al., 2011). For instance, canine renal
cystadenocarcinoma and nodular dermatofibrosis
(Jonasdottir et al., 2000; Lingaas et al., 2003) and
canine osteosarcoma (Phillips et al., 2010) are well-
known examples of syndromes linked to genetic con-
ditions common to both dogs and man. The former
complex was linked to a specific mutation also found
in people affected by a similar syndrome; in the latter
a linkage to a specific locus was found in both species.
These findings underline the value of comparative
studies in human and veterinary oncology as part of
the ‘One Health’ concept (Breen, 2009).
The present study is based on the Swiss Canine
Cancer Registry (Gr€untzig et al., 2015) and highlights
the influences of age, breed, body size, sex and neuter-
ing status on the development of tumours in dogs. The
size of the Swiss Canine Cancer Registry, which com-
prises 121,963 dogs and 67,943 tumour diagnoses, al-
lows computation of meaningful statistics. To our
knowledge, the Swiss Canine Cancer Registry is themost comprehensive animal cancer registry at a na-
tional level.
Materials and Methods
Data Source
The data originated from the Swiss Canine Cancer
Registry (Gr€untzig et al., 2015) comprising 121,963
diagnostic records of dogs provided by three veteri-
nary diagnostic laboratories in Switzerland: the Vet-
suisse Faculty Institut f€ur Veterin€arpathologie,
Z€urich (IVPZ), the Vetsuisse Faculty Institut f€ur
Tierpathologie, Bern (ITPA) and the Zyto/Histo Di-
agnostik private veterinary diagnostic laboratory
(based in Rorbas Freienstein). The data sets included
diagnostic records from canine samples generated by
three different examination methods: post-mortem
analysis (and subsequent histopathological evalua-
tion), biopsy sampling (with subsequent histopatho-
logical examination) and cytology. Biopsy and
cytology samples are hereafter called ex-vivo samples.
No cases were excluded; however, some parameters
were missing due to incomplete reporting by the sub-
mitting veterinarians. All diagnoses in the Swiss
Canine Cancer Registry were derived from a micro-
scopical examination.
Data Preparation
In different time periods, different terms were used for
the description of age, breed, sex and neutering status.
Those differences were standardized by numerical
coding. The diagnoses were then coded according to
the tumour topographical and morphological keys
of the ICD-O-3 (Fritz et al., 2013) and checked for
plausibility using the original patient records. All
tumour diagnoses were based on either histopatholog-
ical or cytological examination. Epidermal cysts were
excluded.
The data included 215 castratedmale dogs with tu-
mours in the testes. Since it is common in those cases
to castrate the patient while sampling the tumour,
those dogs where re-classified as entire at the moment
of tumour diagnosis.
Data sets missing the information on the sex and/or
status of neutering of patients were excluded from the
158 K. Gr€untzig et al.evaluation of the influence of these parameters on
tumour development.
Breed allocation was based on information avail-
able in the diagnostic records, which was usually pro-
vided by the pet owner or by the submitting
veterinarian. A declaration of one breed was accepted
as reported, while a declaration comprising two
breeds (in the case of an apparent mix with recogniz-
able breeds) was categorized according to the breed
mentioned first (i.e. a shepherd-cross was categorized
under shepherd, a shepherdeboxer-cross likewise un-
der shepherd and a boxereshepherd-cross under
boxer). It was assumed that the breed mentioned first
was the one more obvious from the external appear-
ance. Therefore, the breeds defined in this work
cannot be considered pure breeds and a certain influ-
ence of mixed breeding must be acknowledged in the
risk calculations. The proportion of manifestly non-
pure breeds ranged between 0 and 18% in the breeds
considered for analysis (Table 1). Because all such
mixed breeds likely share at least 50% of their genetic
information with the predominant breed, content of
non-breed related genome is maximally 50% in these
animals. This should be taken into account while
interpreting the results of the statistics. As an
example, for the Swiss mountain dog, the breed
with the highest proportion of manifestly crossed
individuals (18.4%), the unrelated genome may
theoretically account for a difference of 9% in the
odds ratio (OR).Table
Frequencies of the 17 most common breeds/breed categories i
and ensuing proportion
Breed/breed category Total numb
Shepherd 12,354 (
Crossbreed 12,193 (
Retriever 11,429 (
Swiss mountain dog 7,774 (
Poodle 7,214 (
Dachshund 6,499 (
Boxer 6,368 (
Schnauzer 2,796 (
Collie 2,206 (
Yorkshire terrier 2,157 (
Cocker spaniel 2,127 (
Setter 2,105 (
Great Dane 1,598 (
Dobermann 1,596 (
Rottweiler 1,470 (
West Highland white terrier 1,316 (
Bulldog 1,016 (
Parson Jack Russell terrier 981 (
Other breeds (including dogs of unknown breeds) 38,764 (
Total of all breeds 121,963 (
*Dogs were allocated to a certain breed based on the owner’s claims; crossbA non-specific allocation such as mixed-breed,
mongrel or crossbreed was categorized under cross-
breed, since it was assumed that a phenotype typical
for a known breed was lacking or not distinct.
The breeds/breed categories most frequently repre-
sented in the data set, each comprising at least 900 in-
dividuals, were retained for analysis of risks related to
breed (Table 1). In a preliminary investigation, the
breed ranking of the data set and the breed ranking
of the Swiss dog population was compared in those
years in which a reference population with known
breed composition was available for use as a control
(1963, 1999 and 2008) (Pospischil et al., 2013). For
those years the patient breed ranking correlated
with that of the reference population, meaning that
there was no significant difference in breed distribu-
tion between the Swiss dog population and the pa-
tient collective. The difference in the distribution of
the individual breeds over time was controlled for
year and proportional distribution.
The remaining breeds and the diagnostic records
with unknown breeds were listed as ‘other breeds’.
The breed category Swiss mountain dog includes Ap-
penzeller mountain dogs, Bernese mountain dogs, En-
tlebucher mountain dogs, large Swiss mountain dogs,
Swiss mountain dogs and mountain dogs. The breed
category retriever includes Chesapeake Bay retriever,
curly coated retriever, flat coated retriever, golden
retriever, Labrador, Nova Scotia duck tolling
retriever, retriever and sandriner (golden retriever1
n the registry and their relative proportions of crossbreeds
of unrelated genome
er* Thereof obviously crossed Ensuing proportion
of unrelated genome
10.13%) 867 (7.02%) 3.51%
10.00%) 12,193 (100%) NS
9.37%) 802 (7.02%) 3.51%
6.37%) 1,410 (18.14%) 9.07%
5.91%) 173 (2.40%) 1.20%
5.33%) 189 (2.91%) 1.46%
5.22%) 127 (1.99%) 0.99%
2.29%) 156 (5.58%) 2.79%
1.81%) 223 (10.11%) 5.06%
1.77%) 7 (0.32%) 0.16%
1.74%) 19 (0.89%) 0.45%
1.73%) 105 (4.99%) 2.49%
1.31%) 44 (2.75%) 1.38%
1.31%) 72 (4.51%) 2.26%
1.21%) 63 (4.29%) 2.15%
1.08%) 3 (0.23%) 0.12%
0.83%) 0 (0.00%) 0.00%
0.80%) 75 (7.65%) 3.83%
31.78%) NS NS NS
100%) 16,528 (13.55%) 7.78%
reeds with dominant traits of a breed were included. NS, not specified.
Analysis of the Swiss Canine Cancer Registry 159crossed with Irish setter). The breed category setter
includes English setter, Gordon setter, Irish red and
white setter, Irish red setter, Irish setter and setter.
The breed category shepherd includes German shep-
herd dog, Beauceron Berger de Beauce, white shep-
herd, Berger de Picardie, Berger de Savoie, Berger
des Pyrenees, Groenendael, Laekenois, Malinois and
Tervueren.
For the examination of the influence of body size on
tumour development two groups were established.
‘Large breeds’ comprised the dobermann, Great
Dane, retriever, rottweiler, Swiss mountain dogs,
shepherd and setter. ‘Small breeds’ comprised the
bulldog, dachshund, Parson Jack Russell, West High-
land white terrier and Yorkshire terrier.Statistical Evaluation
Data editing and statistical analyses were performed
using Stata Software (Stata Corp., 2011; Stata Statis-
tical Software: Release 12; College Station, Texas,
USA). Statistical analyses were carried out using a
Chi-Square/Fisher’s exact test. Significant univari-
able variables were further integrated in amultiple lo-
gistic regression model using binary logistic models
and stepwise backward procedure. The following var-
iables were included in the model as fixed terms: sex,
neutering status, breed, age, year, method of exami-
nation and canton of origin. The first four variables
are random variables related to the animals and
were also used for the specific evaluations on cancer
frequency. The three latter variables were random
factors related to time, examination method and
spatial distribution. The underlying Stata model for
the multiple logistic regression was <logistic vary
varx1 varx2 varx3 varx4 varx5 varx6 varx7>,
whereby vary ¼ tumour, varx1 ¼ sex,
varx2 ¼ neutering status, varx3 ¼ breed,
varx4 ¼ age, varx5 ¼ year of examination,Table
Risk of developing the most common tumour typ
Tumour type Odds ratios and [95% confidence i
All methods
Adenoma, adenocarcinoma 1.337 [1.318, 1.35
Fibroma, fibrosarcoma 0.904 [0.878, 0.93
Haemangioma, haemangiosarcoma 0.889 [0.862, 0.91
Lymphoma 0.953 [0.929, 0.97
Mast cell tumour 1.005 [0.984, 1.026
Melanocytic tumour 0.843 [0.820, 0.86
Osteoma, osteosarcoma 1.004 [0.959, 1.052
Squamous cell carcinoma 0.888 [0.856, 0.92
Statistically significant results are in bold. The number of observations wavarx6 ¼ method of examination, varx7 ¼ canton of
origin. P <0.05 was considered to be significant and
ORs with 95% confidence intervals (CIs) were calcu-
lated. The power was set at 0.8. In the statistical eval-
uation, crossbreeds were used as the standard for
comparisons with the remaining breeds, since they
were assumed to have the largest genetic variation.
For the evaluation of influence of sex and neutering
status (Fig. 6) on overall tumour development, the
data were divided into two subsets based on the exam-
ination method: post-mortem samples and ex-vivo
samples. The results of the following three groups
were compared: post-mortem samples, ex-vivo sam-
ples and all samples. For the evaluation of the influ-
ence of sex and neutering status on most common
tumour diagnoses and locations (Tables 2e4), the
total data set (all samples) was compared with the
post-mortem sample data subset. The analyses of
the influence of age on specific tumour development
was biased by the low number of cases aged >15
years. Therefore, results are shown until the age of 15.Results
The Swiss Canine Cancer Registry consists of records
from 126,693 dogs that underwent pathological ex-
amination. The number of patients with confirmed
tumours was 63,214 (51.83%). Some dogs were diag-
nosed with multiple primary tumours, adding up to a
total of 67,943 diagnosed tumour lesions.
The age distribution has been previously presented
(Gr€untzig et al., 2015). A large number of the dogs
were crossbred (n ¼ 12,193; 10.00%). Breed distribu-
tion is given in Table 1. The collective comprised
56,062 (45.97%) male dogs and 61,754 (50.63%) fe-
male dogs. The neutering status was recorded as
entire in 59,902 (49.11%) dogs, neutered in 26,127
(21.42%) dogs (8,845 male, 17,731 female) and not
specified in 35,934 (29.46%) dogs.2
es, comparing sexes and sampling methods
ntervals] for females compared with males (OR ¼ 1) in samples collected by
Post mortem
6] 1.106 [1.075, 1.137]
0] 1.081 [0.966, 1.211]
7] 0.908 [0.842, 0.979]
7] 0.968 [0.926, 1.011]
] 0.982 [0.874, 1.103]
7] 0.969 [0.843, 1.115]
] 1.031 [0.949, 1.121]
2] 0.784 [0.686, 0.896]
s: 126,692 for all methods and 27,753 for post-mortem samples.
Table 3
Risk of developing the most common tumour types, comparing neutering status and sampling methods
Tumour type Neutered males compared with entire males (OR ¼ 1) Neutered females compared with entire females (OR ¼ 1)
In ex-vivo and post-mortem samples In post-mortem samples In ex-vivo and post-mortem samples In post-mortem samples
OR and [95%CI] OR and [95%CI] OR and [95%CI] OR and [95%CI]
Adenoma, adenocarcinoma 1.384 [1.218, 1.573] 1.730 [1.339, 2.237] 0.650 [0.604, 0.699] 1.183 [0.967, 1.446]
Fibroma, fibrosarcoma 1.181 [0.984, 1.417] 0.824 [0.361, 1.880] 1.183 [1.010, 1.386] 1.128 [0.559, 2.276]
Haemangioma,
haemangiosarcoma
0.995 [0.832, 1.188] 1.005 [0.665, 1.519] 1.610 [1.374, 1.886] 2.438 [1.606, 3.703]
Lymphoma 1.150 [1.006, 1.315] 1.558 [1.130, 2.150] 1.349 [1.194, 1.525] 2.295 [1.694, 3.111]
Mast cell tumour 1.150 [1.008, 1.313] 3.461 [1.515, 7.910] 1.190 [1.080, 1.312] 2.980 [1.355, 6.551]
Melanocytic tumour 0.962 [0.817, 1.133] 0.868 [0.251, 3.002] 1.407 [1.216, 1.627] 4.425 [1.619, 12.094]
Osteoma, osteosarcoma 1.555 [1.218, 1.985] 2.022 [1.151, 3.554] 1.210 [0.982, 1.491] 1.420 [0.887, 2.275]
Squamous cell carcinoma 0.771 [0.588, 1.010] 3.811 [1.515, 9.585] 1.287 [1.051, 1.576] 1.969 [0.502, 7.719]
Statistically significant results are in bold. The number of observations was: 43,006 for ex-vivo and post-mortem samples and 7,357 for post-mortem
samples for neutered versus entire males and 46,387 for ex-vivo and post-mortem samples and 6,144 for post-mortem samples for neutered versus
entire females.
160 K. Gr€untzig et al.The following results show the influence of breed on
the most common tumour types, as well as of age,
body size, sex and neutering status on the overall
and specific tumour occurrence. In addition, the in-
fluence of sex and neutering status on the anatomical
locations is reported. Their occurrence patterns over
the years are also included. The classification and dis-
tribution of the tumour species of the data set is pre-
sented in Supplementary Table 1.Table 4
Risk of developing a tumour in the most common
locations, comparing sexes and sampling methods
Tumour location Females compared with males (OR ¼ 1)
In ex-vivo and
post-mortem samples
In post-mortem samples
OR and [95%CI] OR and [95%CI]
Skin 0.895 [0.886, 0.905] 0.964 [0.902, 1.029]
Mammary gland 3.264 [3.163, 3.369] 4.115 [3.486, 4.858]
Soft tissues 1.027 [1.011, 1.043] 0.930 [0.886, 0.975]
Blood, haemopoietic
system
0.912 [0.880, 0.946] 0.982 [0.930, 1.038]
Neoplasia of bones,
joints, cartilage
0.975 [0.936, 1.016] 0.961 [0.892, 1.035]
Endocrine gland 0.996 [0.951, 1.043] 1.089 [1.032, 1.15]
Gastrointestinal tract 0.741 [0.726, 0.756] 1.005 [0.962, 1.050]
Lymph nodes 0.923 [0.852, 0.999] 0.942 [0.837, 1.060]
Oral cavity, pharynx 0.954 [0.911, 0.999] 0.964 [0.846, 1.097]
Respiratory system,
intrathoracic
organs
0.948 [0.914, 0.982] 1.024 [0.979, 1.071]
Urinary organs 1.034 [0.965, 1.108] 1.059 [0.951, 1.178]
Unspecified location 1.032 [1.016, 1.047] 0.968 [0.936, 1.001]
Significant results in bold. The number of observations was 126,692 for
ex-vivo and post-mortem samples and 27,753 for post-mortem sam-
ples.Adenoma/Adenocarcinoma (ICD-O 8140)
Adenomas/adenocarcinomas (n ¼ 12,293, 18.09%)
were the most common tumour diagnosed overall.
From 1955 to 1985, approximately 30e40% of the
diagnosed tumours were adenomas/adenocarci-
nomas. After 1985, the frequency of these diagnoses
progressively dropped to 12% in 2008 (Fig. 1). Ade-
nomas/adenocarcinomas were most commonly diag-
nosed in the mammary gland (n ¼ 6,805; 55.36%)
and in the gastrointestinal tract (n ¼ 1,020; 8.30%).
Using multiple regression analysis, the ORs of the
dog breeds/breed categories developing an ade-
noma/adenocarcinoma were compared with those of
the crossbreds (OR ¼ 1). The Yorkshire terrier, the
poodle, the cocker spaniel, the collie, the dachshund
and the West Highland white terrier presented with
significantly higher ORs in comparison with cross-
breds and the other breeds/breed categories included
in the analysis. Breeds/breed categories with lower
ORswere the rottweiler, the Great Dane, the bulldog,
the retriever, the dobermann, the schnauzer, the
Swiss mountain dog, the setter, the boxer and the
shepherd (Fig. 2).Mast Cell Tumours (ICD-O 9740)
Among the 67,943 neoplasms, 4,415 (6.50%) were
diagnosed as a mast cell tumour. Between 1955 and
2008 the relative frequency of mast cell tumours
rose with considerable fluctuations from 2.1% to
8.4% of the overall tumour diagnoses (Fig. 1). Mast
cell tumours (n ¼ 4,415) were mainly diagnosed in
the skin (n ¼ 4,324; 97.94%). The boxer showed
outstanding significantly higher ORs of developing
a mast cell tumour in comparison with crossbreds
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Fig. 1. Relative tumour frequencies between 1955 and 2008.
Analysis of the Swiss Canine Cancer Registry 161and to the other breeds/breed categories. Other
breeds with higher risk were the Swiss mountain
dogs, the retriever, the bulldog and the Parson Jack
Russell terrier. Breeds/breed categories with lower
ORs were the collie, the rottweiler, the West High-
landwhite terrier, the shepherd, the poodle, the York-
shire terrier, the cocker spaniel, the dobermann and
the dachshund (Fig. 2).Lymphoma (ICD-O 9590, 9591, 9700)
Among the 67,943 diagnosed tumours, 2,955 (4.35%)
were lymphomas. Between 1955 and 2008 the relative
frequency of lymphoma decreased from 6.52% to
3.97% per year and from 1968 to 1988 it was around
2% (Fig. 1). Lymphomas (n ¼ 2,955) were most
commonly diagnosed in the lymph nodes
(n ¼ 1,362; 46.09%) and in unspecified locations
(n¼ 425; 14.38%), followed by the blood and haemo-
poietic system (n ¼ 380; 12.86%), skin (n ¼ 234;
7.92%), the spleen (n ¼ 206; 6.97%) and the liver
(n ¼ 69; 2.34%). Logistic regression revealed that
the rottweiler has a markedly higher OR of devel-
oping a lymphoma than crossbreds and other
breeds/breed categories included in the analysis.
Another breed category with higher ORs was the
Swiss mountain dog. The poodle, the Yorkshire ter-rier, the dachshund, the retriever and the shepherd
had lower ORs for lymphoma (Fig. 2).
Melanocytic Tumours (ICD-O 8720, 8730)
Among the 67,943 neoplasms diagnosed, 2,466
(3.63%) were melanocytic tumours. From 1955 to
2008 the relative frequency of melanocytic tumours
rose from under 2% to over 4% (Fig. 1). The most
common anatomical locations for melanocytic tu-
mours (n ¼ 2,466) were the skin (n ¼ 2,309; 93.6%)
and the oral cavity/nasopharynx (n ¼ 106; 4.3%).
Multiple regression analysis revealed that the ORs
for the following dog breeds/breed categories of devel-
oping amelanocytic tumour were higher than those of
crossbreds and the other breeds/breed categories
included in the analysis: the setter, the schnauzer,
the rottweiler, the retriever, the poodle, the dober-
mann, the dachshund and the cocker spaniel. The
bulldog, the West Highland white terrier, the collie,
the boxer and the Great Dane presented with lower
ORs for melanocytic tumours (Fig. 2).
Fibroma/Fibrosarcoma (ICD-O 8810, 8812)
Among the 67,943 tumours, 2,309 (3.40%) were
diagnosed as a fibroma/fibrosarcoma. Between 1960
and 1996 the relative frequency of fibroma/
Fig. 2. Odds ratios (ORs) and 95% confidence intervals (CIs) for the most common dog breeds/breed categories of developing specific
tumours compared with those for crossbreds (OR ¼ 1). The number of observations was 126,692.
162 K. Gr€untzig et al.
Analysis of the Swiss Canine Cancer Registry 163fibrosarcoma increased with several fluctuations from
1.16% to 6.71% of the total tumour number. From
1996 to 2008 their relative frequency was between
2.10% and 3.56% (Fig. 1). The most common
anatomical locations for fibroma/fibrosarcoma
(n ¼ 2,309) were the soft tissues (n ¼ 1,080;
46.77%) and the skin (n ¼ 1,040; 45.04%). The
setter, the Swiss mountain dog, the rottweiler, the
retriever, the dobermann, the boxer and the shepherd
had higher ORs of developing fibroma/fibrosarcoma
than did crossbreds and the other breeds/breed cate-
gories included in the analysis. The West Highland
white terrier, the Yorkshire terrier, the dachshund
and the poodle presented with lower ORs for fi-
broma/fibrosarcoma (Fig. 2).Haemangioma/Haemangiosarcoma (ICD-O 9120, 9121)
Among the 67,943 diagnosed tumours, 1,904 (2.80%)
were a haemangioma/haemangiosarcoma. Between
1955 and 2008 the relative frequency of these tumours
rose from 0 to 3.45%, reaching a peak of 7.92% in
1996 (Fig. 1). Themost common anatomical locations
for haemangioma/haemangiosarcoma (n ¼ 1,904)
were soft tissues (n ¼ 1,203, 63.18%) and the skin
(n ¼ 459; 24.11%), followed by the blood/
haemopoietic system (n¼ 113; 5.93%). The shepherd
(OR 1.806 [CI ¼ 1.518, 2.150]) and the boxer (OR
1.850 [CI ¼ 1.506, 2.261]) showed higher ORs of
developing a haemangioma/haemangiosarcoma
than crossbreds and the other breeds/breed categories
included in the analysis. The West Highland white
terrier, the Yorkshire terrier, the rottweiler, the
poodle, the dobermann, the Great Dane, the cocker
spaniel and the dachshund presented with lower
ORs for haemangioma/haemangiosarcoma (Fig. 2).Fig. 3. Odds ratios (ORs) and 95% confidence intervals (CIs) for
patients at different ages of developing different tumour
types compared with patients aged <1 year (OR ¼ 1).
The number of observations was: 126,692 for adenoma/
adenocarcinoma and 126,665 for lymphoma.Squamous Cell Carcinoma (ICD-O 8070, 8071, 8078)
Among the 67,943 tumours, 1,324 (1.95%) were
diagnosed as a squamous cell carcinoma. After a
peak of 7.46% in 1958 the relative frequency of squa-
mous cell carcinoma fluctuated between 0.94% and
4.02% of the overall tumour diagnoses until 1999.
From 2000 to 2008 it was between 1.47% and
2.29% (Fig. 1). The high numbers in the 1950s might
result from a bias due to the low amount of tumour
data available from this period. The most common
anatomical locations for squamous cell carcinoma
(n ¼ 1,324) were unspecified locations (n ¼ 615;
46.5%), the skin (n ¼ 601; 45.4%) and the oral cav-
ity/nasopharynx (n ¼ 56; 4.23%). Here, results for
the schnauzer revealed a seven-fold higher risk (OR
7.712 [CI ¼ 6.031, 9.860]) of developing a squamous
cell carcinoma than the other breeds/breed categoriesincluded in the analysis. The boxer presented with a
lower OR for squamous cell carcinoma (Fig. 2).
Osteoma/Osteosarcoma (ICD-O 9180)
Among the 67,943 tumours, 842 (1.24%) were diag-
nosed as an osteoma/osteosarcoma. From 1955 to the
late 1960s the relative frequency of osteoma/osteosar-
coma was variable, ranging between 6% and 0% of
the overall tumour diagnoses. In the 1970s and 1980s
it was constantly under 1%. Up to 2008 it rose to
1.56%, with two peaks over 2% in the 1990s (Fig. 1).
The most common anatomical locations for osteoma/
osteosarcoma were bones and joints (n ¼ 746;
88.60%), followed by skin (n ¼ 26; 3.08%). The rott-
weiler (OR 3.321 [CI ¼ 2.321, 4.752]) and the Great
Dane (OR 1.936 [CI ¼ 1.248, 3.003]) presented
with a higher risk of developing an osteoma/osteosar-
coma than crossbreds and the other breeds/breed cat-
egories included in the analysis. The bulldog, the
dachshund, the West Highland white terrier, the
Parson Jack Russell terrier, the Yorkshire terrier, the
poodle, the cocker spaniel and the schnauzer presented
with lower ORs for osteoma/osteosarcoma (Fig. 2).
Influence of Age on Overall Tumour Development
Analyses of the influence of age revealed that the risk
of developing adenoma/adenocarcinoma, melano-
cytic tumours and squamous cell carcinoma increased
almost constantly with age. The risk of developing
mast cell tumours, fibroma/fibrosarcoma, haeman-
gioma/haemangiosarcoma and osteoma/osteosar-
coma was only moderately influenced by increasing
164 K. Gr€untzig et al.age after the age of 3, 4, 5 and 6 years, respectively.
The risk of developing a lymphoma increased
constantly with age until 6 years and decreased there-
after (Figs. 3 and 4).Influence of Breed on Overall Tumour Development
Boxer (OR 1.700 [CI¼ 1.592, 1.815]), cocker spaniel
(OR 1.504 [CI ¼ 1.365, 1.658]), poodle (OR 1.443
[CI ¼ 1.354, 1.537]), Swiss mountain dog (OR
1.357 [CI ¼ 1.278, 1.440]), dachshund (OR 1.305
[CI ¼ 1.223, 1.392]), setter (OR 1.299 [CI ¼ 1.179,
1.431]), schnauzer (OR 1.289 [CI ¼ 1.182, 1.405])
and retriever (OR 1.278 [CI ¼ 1.211, 1.348]) wereFig. 4. Odds ratios (ORs) and 95% confidence intervals (CIs) for patie
with patients aged <1 year (OR ¼ 1). The number of observa
sarcoma, 126,411 for osteoma/osteosarcoma; 126,593 for haema
126,665 for squamous cell carcinoma.at higher risk of developing a tumour than were cross-
breds. Great Dane (OR 0.532 [CI ¼ 0.475, 0.596]),
bulldog (OR 0.615 [CI ¼ 0.537, 0.704]), West High-
land white terrier (OR 0.701 [CI ¼ 0.622, 0.789]),
Parson Jack Russell terrier (OR 0.791 [CI ¼ 0.690,
0.906]), rottweiler (OR 0.829 [CI ¼ 0.739, 0.929]),
dobermann (OR 0.833 [CI ¼ 0.747, 0.929]), collie
(OR 0.840 [CI ¼ 0.764, 0.923]), shepherd (OR
0.872 [CI ¼ 0.827, 0.919]) and Yorkshire terrier
(OR 0.897 [CI ¼ 0.816, 0.986]) were at lower risk
of developing a tumour than crossbreds (Fig. 5).
There was no generally higher risk for defined
breeds/breed categories as a whole group compared
with mixed breeds.nts at different ages of developing different tumour types compared
tions was: 126,682 for mast cell tumour, 126,665 for fibroma/fibro-
ngioma/haemangiosarcoma; 126,651 formelanocytic tumours and
Fig. 5. Odds ratio (OR) for defined breeds/breed categories of
developing a tumour comparedwith crossbreds. The num-
ber of observations was 126,692.
Fig. 6. Odds ratios (OR)of developing a tumour by sex and castra-
tion status, subclassifiedby examinationmethod.Thenum-
ber of observations was: 1 35,649; 2 7,357; 3 43,006; 4 40,243;
5 6,144; 6 46,387; 7 95,746; 8 26,733; 9 122,479.
Analysis of the Swiss Canine Cancer Registry 165Influence of Body Size on Overall Tumour Development
There was no general difference in the risk of devel-
oping a tumour for either body size group. However,
the small breed group was three times more
frequently affected by tumours of the mammary
glands (OR 3.034 [CI ¼ 2.834, 3.256]) and had a
54.82% higher risk of developing a tumour of the
endocrine glands (OR 1.548 [CI ¼ 1.190, 2.014])
than the large breed group. Small breeds were at
less risk of developing tumours in the following loca-
tions: soft tissues (OR 0.402 [CI ¼ 0.361, 0.448]),
skin (OR 0.819 [CI ¼ 0.774, 0.868]), retroperito-
neum and peritoneum (OR 0.308 [CI ¼ 0.141,
0.672]), respiratory system and intrathoracic organs
(OR 0.430 [CI ¼ 0.264, 0.439]), other female sexual
organs (OR 0.274 [CI ¼ 0.184, 0.408]), bones, joints
and articular cartilage (OR 0.192 [CI ¼ 0.131,
0.282]).Influence of Sex and Neutering Status on Overall Tumour
Development
A closer look at the influence of sex and neutering sta-
tus on overall tumour prevalence showed that the re-
sults depend on the examination method (Fig. 6). In
post-mortem samples, tumour risk was 81.64%higher
(OR 1.816 [CI ¼ 1.570, 2.101]) for neutered males
than for entire males (by definition OR ¼ 1.000).
Tumour risk was two times higher (OR 2.070
[CI ¼ 1.831, 2.340]) for neutered females than for
entire females. In ex-vivo samples, tumour risk was
only 6.18% higher (OR 1.062 [CI ¼ 1.010, 1.117])
for neutered males than for entire males. Tumour
risk was 14.20% lower (OR 0.858 [CI ¼ 0.823,
0.894]) for neutered females than for entire females
(Fig. 6).Influence of Sex and Neutering Status on Specific Tumour
Development
Hereafter, only results significant in both investigated
groups (i.e. the total data set and the subset of post-
mortem samples) are reported. All results are pre-
sented in Tables 2e5. The distribution of tumour
locations for the investigated groups is presented in
Supplementary Tables 2e5.
The ORs for female dogs of developing an ade-
noma/adenocarcinoma were significantly higher
than those for male dogs. Females presented with
lower ORs for haemangioma/haemangiosarcoma
and squamous cell carcinoma than males (Table 2).
Neutered male dogs presented with higher ORs of
developing the following tumours than entire male
dogs: adenoma/adenocarcinoma, lymphoma, mast
cell tumour and osteoma/osteosarcoma (Table 3).
Neutered female dogs had lower ORs of developing
adenoma/adenocarcinoma than entire females. Neu-
tered female dogs presented with higher ORs for the
following tumours: haemangioma/haemangiosar-
coma, lymphoma, mast cell tumour and melanocytic
tumour (Table 3).Influence of Sex and Neutering Status on Tumour Location
Female dogs presented with higherORs of developing
mammary gland tumours than male dogs (Table 4).
Neutered male dogs presented with higher ORs for
skin tumours, tumours of the blood and the haemo-
poietic system, tumours of the endocrine glands, the
respiratory system and intrathoracic organs and un-
specified locations than entire male dogs (Table 5).
Neutered female dogs presented with higher ORs
for skin and soft tissue tumours, tumours of the blood
Table 5
Risk of developing a tumour in the most common locations, comparing neutering status and sampling methods
Tumour location Neutered males versus entire males (OR ¼ 1) Neutered females versus entire females (OR ¼ 1)
In ex-vivo and
post-mortem samples
In post-mortem samples In ex-vivo and
post-mortem samples
In post-mortem samples
OR and [95%CI] OR and [95%CI] OR and [95%CI] OR and [95%CI]
Skin 1.088 [1.020, 1.161] 2.303 [1.473, 3.601] 1.208 [1.146, 1.274] 2.226 [1.637, 3.028]
Mammary gland 1.099 [0.842, 1.434] 0.639 [0.077, 5.317] 0.411 [0.383, 0.440] 0.574 [0.408, 0.806]
Soft tissues 1.352 [1.247, 1.466] 1.169 [0.843, 1.621] 1.278 [1.196, 1.366] 2.226 [1.637, 3.028]
Blood, haemopoietic system 1.385 [1.069, 1.795] 1.974 [1.248, 3.123] 1.549 [1.208, 1.986] 1.970 [1.251, 3.102]
Bones, joints, cartilage 1.492 [1.203, 1.850] 1.475 [0.881, 2.470] 1.258 [1.043, 1.517] 1.136 [0.714, 1.807]
Endocrine gland 1.563 [1.159, 2.106] 1.705 [1.155, 2.516] 1.262 [0.965, 1.650] 1.101 [0.790, 1.535]
Gastrointestinal tract 1.124 [0.999, 1.265] 1.579 [1.178, 2.118] 1.472 [1.296, 1.672] 1.975 [1.524, 2.558]
Lymph nodes 1.551 [1.000, 2.408] 2.318 [1.035, 5.195] 1.105 [0.719, 1.700] 1.137 [0.465, 2.778]
Other male sexual organs
(penis, prostate gland, scrotum)
1.279 [0.875, 1.870] 1.729 [0.990,3.020] no observations no observations
Other female sexual organs
(vagina, uterus, ovary)
no observations no observations 1.012 [0.747, 1.370] 0.332 [0.127, 0.870]
Oral cavity, pharynx 1.267 [0.998, 1.608] 0.358 [0.085, 1.517] 1.348 [1.094, 1.661] 4.733 [2.009, 11.152]
Respiratory system, intrathoracic
organs
1.498 [1.176, 1.909] 1.738 [1.306, 2.313] 1.554 [1.271, 1.900] 1.784 [1.402, 2.271]
Urinary organs 1.419 [0.894, 2.251] 1.837 [0.947, 3.566] 1.695 [1.203, 2.388] 2.656 [1.565, 4.508]
Unspecified location 1.133 [1.042, 1.233] 1.649 [1.275, 2.132] 1.005 [0.939, 1.075] 1.803 [1.441, 2.254]
Significant results are in bold. The number of observations was: 43,006 for ex-vivo and post-mortem samples and 7,357 for post-mortem samples for
neutered versus entire males and 46,387 for ex-vivo and post-mortem samples and 6,144 for post-mortem samples for neutered versus entire fe-
males.
166 K. Gr€untzig et al.and the haemopoietic system, the gastrointestinal
tract, the oral cavity and pharynx, the respiratory sys-
tem and intrathoracic organs and the urinary organs
than entire female dogs. They had lower ORs for tu-
mours of the mammary gland (Table 5).
To verify the results above, the investigations for
neutered females versus entire females were repeated,
excluding tumours of the mammary gland. The devi-
ations from the results that included mammary gland
tumours were negligible (Supplementary Tables
6e7). An exception was the result for adenoma/
adenocarcinoma in post-mortem samples: neutered
females had a higher risk for adenoma/adenocarci-
noma than entire females when mammary tumours
were excluded.Discussion
The exceptionally large data set of the Swiss Canine
Cancer Registry allowed multiple logistic regression,
which was not always possible in the case of other reg-
istries and renders comparisons difficult. However,
the data sets may be biased over time and further con-
founders could substantially influence the results. To
overcome such influences specifically and to raise
sensitivity, more general diagnostic terms were used.
Further obstacles to comparison are typical issues
related to the reproducibility of diagnoses in pathol-ogy, due to criteria for certain diagnoses changing
over time and to the clearly subjective factor in histo-
pathological diagnoses (Brønden et al., 2007;
Pospischil and Folkers, 2015). In this study, the
influence of different time periods on techniques and
state of the art in tumour diagnoses was taken into
account by including the year of diagnosis as a
variable in the statistical evaluation.
For the sake of simplicity only findings determined
to be significant in the present work will be discussed
below, while discussion of previously described results
not confirmed by the present analysis will be omitted.
Adenoma/adenocarcinoma was the most frequent
tumour diagnosis in dogs. Its relative proportion in
total tumour diagnoses dropped from 40.6% in
1980 to 12.3% in 2008. In 1980, 92.80% of all exam-
ined canine patients (n ¼ 2,194) were entire. Howev-
er, the relative proportion of entire animals
decreased to 55.6% of total patients (n ¼ 7,879) in
2008. Since over 60% of the adenomas/adenocarci-
nomas were found in the sexual organs, the
increasing tendency to neuter dogs could be one
reason for the decrease in relative frequency of ade-
noma/adenocarcinoma. A similar tendency was
observed for canine mammary cancers in Italy by
Merlo et al. (2008). Another aspect is the refinement
in diagnostics over time, leading to a broader diver-
sity of tumour diagnoses.
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nocytic tumours and haemangioma/haemangiosar-
coma rose fairly constantly from 1955 to 2008. Since
neutered female dogs are more frequently affected
by these tumour types, the increase in neutering fre-
quency over time might be partly responsible for
this development.
Vascellari et al. (2009) reported a frequency of 3%
for canine lymphomas in the animal tumour registry
of two provinces in Northern Italy between 2005
and 2008, which is comparable with our data
(4.88% lymphomas).
The relative frequency of fibroma/fibrosarcoma
increased from 6.52% in 1955 to 10.76% in 1996
and decreased to 5.41% in 2008. These results are
in contrast with the increase in feline fibroma/fibro-
sarcoma (20%) observed in Switzerland in the
1990s (Graf et al., 2016). However, in cats a strong
connection between vaccination and the develop-
ment of sarcomas at sites of injection is under discus-
sion (Henry, 2013). Such a connection has not been
observed consistently in dogs.
The peaks in the relative frequency of tumour types
between 1996 and 1999 were due to very high
numbers of the respective tumours in the data sent
in by the Vetsuisse Faculty Institut f€ur Tierpatholo-
gie, Bern (ITPA). It is likely that these sudden in-
creases were artificially generated by tumour studies
in the institute. This is an example of factors that
can skew tumour frequencies in the present study
setting.
It is a well-known fact that overall tumour risk in-
creases with age. In our data this was confirmed for
adenoma/adenocarcinoma, melanocytic tumours
and squamous cell carcinoma. Interestingly, the
following tumour types in our study showed a fre-
quency pattern deviating from that described above.
The lymphoma risk peaked at 6 years of age. This
finding is comparable with results of an Italian study
(Merlo et al., 2008), but contradicts data from another
study from Italy, which did not, however, perform
multivariate statistics (Vascellari et al., 2009). There
was no clear age-related incidence of haemangioma/
haemangiosarcoma and mast cell tumour in patients
>5 years of age. This could indicate the influence of
the genetic background or other external factors.
Findings related to the effect of neutering status on
tumour development were partly dependent on the
examination method, specifically on whether the an-
imal was dead or alive at the time of diagnosis. Over-
all tumour incidence in post-mortem samples was
higher in neutered than in entire dogs, suggesting
bias through investigation of mammary glands and
testes in ex-vivo materials. The difference of the
ORs for specific tumours in female dogs comparedwith male dogs was small in both sampling groups.
Females were at a lower risk for haemangioma/hae-
mangiosarcoma and squamous cell carcinoma
compared with males, while they had a 33.7% higher
risk for adenoma/adenocarcinoma overall. In post-
mortem samples the risk was only 10.6%higher for fe-
males than for males. However, when the neutering
status was taken into consideration, the difference be-
tween the sampling groups was higher, confirming the
suggested bias mentioned above.
Neutered dogs were shown to have a higher risk of
developing tumours in various locations other than
the sexual organs, which is consistent with data
from other studies (Brønden et al., 2010; Torres de
la Riva et al., 2013; Zink et al., 2014). Other authors
report that tumour risk in the mammary glands in
entire dogs is higher than in neutered animals, a
finding supported by our data (MacVean et al.,
1978; Porrello et al., 2006; Brønden et al., 2010;
Henry, 2013).
Neutered male and female dogs showed higher
ORs for lymphoma and mast cell tumour. Neutered
female dogs additionally showed higher ORs for mel-
anocytic tumours and haemangioma/haemangiosar-
comas, as did neutered male dogs for adenoma/
adenocarcinoma and osteoma/osteosarcoma. These
correlations need to be validated by future research.
In the present study, breed predispositions for
neoplasia in general, arranged in descending order,
were recorded in boxers, cocker spaniels, poodles,
Swiss mountain dogs, dachshunds, setters, schnauzers
and retrievers. In contrast, Great Danes, bulldogs,
West Highland white terriers, Parson Jack Russell
terriers, rottweilers, dobermanns, collies, shepherds
and Yorkshire terriers showed a lower risk of devel-
oping a tumour compared with crossbreds.
Other authors report the boxer, the flat coated
retriever and the golden retriever (subsets of the cate-
gory of retriever in our study), the Bernese mountain
dog and the Saint Bernard (subsets of the Swiss moun-
tain dog) and the giant schnauzer (a subset of schnau-
zer) as beingmore susceptible to tumour development
(Brønden et al., 2010; Bell et al., 2012; Dobson, 2013).
German shepherd dogs were at a lower risk of tumour
development in the Danish Veterinary Cancer
Registry (Brønden et al., 2010). These findings are
roughly confirmed by our study, taking into account
the differences in breed allocation.
For a better overview and clinical relevance we
hereafter only discuss outstanding results of the influ-
ence of breed on the development of some specific tu-
mours.
The boxer had an almost five times higher risk (OR
4.926 [CI ¼ 4.343, 5.587]) of developing a mast cell
tumour and a 1.85 times higher risk of
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[CI ¼ 1.506, 2.261]). Similar findings have been
described in the literature (Misdorp, 2004; Gough
and Thomas, 2010).
Schnauzers were two times more susceptible for
melanocytic tumour and seven times more susceptible
for squamous cell carcinoma than crossbreds. Mela-
nocytic tumour is known to occur more frequently
in dogs with darkly pigmented skin or oral mucosa
(e.g. schnauzers) (Gough and Thomas, 2010;
Dobson, 2013). The OR for squamous cell
carcinoma in the schnauzer was higher than
expected, which might indicate either a genetic or
an environmental factor associated with the
geographical area from which the samples originate.
Gough and Thomas (2010) report a predisposition
of the schnauzer for squamous cell carcinoma of the
digit in a case series.
The shepherd had higher ORs (OR 1.806
[CI ¼ 1.518, 2.150]) of developing a haemangioma/
haemangiosarcoma, which is consistent with previous
reports (Gough and Thomas, 2010).
The rottweiler (OR 3.321 [CI¼ 2.321, 4.752]) and
theGreat Dane (OR 1.936 [CI¼ 1.248, 3.003]) had a
higher risk of developing an osteoma/osteosarcoma.
This tendency has also been reported in the literature
(Gough and Thomas, 2010). Reported risk factors for
canine osteosarcoma are high weight, high height,
early neutering and breed predisposition (e.g. Irish
wolfhound, Saint Bernard, Great Dane, rottweiler,
Irish setter, dobermann, golden retriever, Labrador
retriever and Leonberger) (Porrello et al., 2006;
Butler et al., 2013). Genetic factors have been
observed to differentiate rottweilers and golden
retrievers with regard to the incidence of
spontaneous appendicular osteosarcoma,
independent of sex, age and histological
classification (Thomas et al., 2009). The most signifi-
cant difference was the deletion of the WT1 gene in
48% of the rottweiler tumour cases, while this did
not occur in any of the golden retrievers. A recent
study suggests that ‘weight-bearing stress during the
period of high proliferative activity in the long bones
associated with growthmay increase the risk of canine
primary bone cancer’ (Anfinsen et al., 2015).
There was, in the present study, no significant dif-
ference between mixed breeds and the examined
breeds/breed categories with regard to general cancer
risk, which contrasts with the report of Brønden et al.
(2007), who showed a twofold increased risk of devel-
oping tumours for pure breeds compared with mixed
breeds. Vascellari et al. (2009), in addition, described
the estimated crude annual incidence rate for malig-
nant tumours as twofold higher in purebred dogs
than in crossbreed dogs (Vascellari et al., 2009).Different data collecting or breed definition standards
might be the reason for these contradictory results.
Since the declaration of breed is usually provided by
the owner of the dog, it is necessary to avoid future un-
certainties related to breed declaration through ge-
netic testing. Today, the examination of the genome
of dogs and the identification of single nucleotide
polymorphism (SNP) haplotypes allows the classifica-
tion of dog breeds on the basis of genetic relationship
(Vonholdt et al., 2010). This will be addressed in a
follow-up study. Additionally, the breed-related risks
found in the present study were confirmed through
analysis of the newest data from the Swiss Canine
Cancer Registry of 2009e2013 (data not shown).
Small breeds were at a higher risk of developing tu-
mours of the mammary gland and the endocrine
glands than large breeds. The following tumour loca-
tions were less likely in small breeds than in large
breeds: the respiratory system and intrathoracic or-
gans, the blood and haemopoietic system, soft tissues,
skin, retroperitoneum and peritoneum, other female
sexual organs, bones, joints and articular cartilage.
Contrasting findings, such as a lower malignant
mammary tumour incidence in small breed dogs,
are suggested by Itoh et al. (2005). Further investiga-
tions will be necessary to verify those results. The un-
expectedly high risk of developing tumours of the
mammary glands for small breeds in our data could
be explained by their tendency to have shorter sexual
cycles (Arnold-Gloor et al., 2011) and therefore
increased exposure to sex hormones during oestrus.
The breeds/breed categories with lower risk of
developing osteoma/osteosarcoma were breeds of
small body size, with the exception of poodles and
schnauzers, which show varying body sizes. These re-
sults suggest that size and castration are predisposing
factors for skeletal tumours.
The large sample size in the present study allowed
a detailed insight into the occurrence of the most
common tumour diagnoses over time and into the
influences of age, breed, body size, sex and neutering
status on canine tumour development. Through the
inclusion of influencing variables in the statistics,
bias factors such as the examination method or the
year of diagnosis were controlled. Naturally, not
all environmental tumour risk factors were recorded
in this retrospective cancer registry and therefore
could not be included in the statistical evaluation.
The clinical relevance still has to be elucidated.
Inmany cases, the results of the analysis of the Swiss
Canine Cancer Registry confirm the findings of other
authors. In some cases, the results were unique or con-
tradicted other studies, implying that further investi-
gations are necessary.
Analysis of the Swiss Canine Cancer Registry 169The reproducibility of cancer epidemiological
studies is greatly affected by the absence of interna-
tional standards for veterinary cancer registries
(Brønden et al., 2007). In addition, the lack of guide-
lines leads to enormous differences in data collection
and consolidation methods among existing veterinary
cancer registries (Brønden et al., 2007; Vascellari et al.,
2009). To achieve a more accurate comparison it is
crucial to define international de jure standards for
veterinary cancer registries. It is desirable to collect
even more primary information from the canine
tumour patient for further epidemiological studies of
canine cancer, such as type of treatment, diet, age
at neutering, obesity (body mass index) and body
size, the presence of other diseases, vaccination
status and environmental factors (e.g. exposure to
cigarette smoke and other husbandry conditions,
daily exercise).Acknowledgments
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